| http://www.w3.org/ns/prov#value | - Existing legislation gave the FDA the authority to grant URL Pharma three years of market exclusivity for the gout indications and seven years of market exclusivity for FMF. Last September, the FDA ordered companies that manufactured, distributed or marketed unapproved, single-ingredient oral colchicine to stop their activities with respect to the drug.The immediate impact of this decision is a dr
|
